A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts

Jad El-Hoss, Duohui Jing, Kathryn Evans, Cara Toscan, Jinhan Xie, Hyunjoo Lee, Renea A. Taylor, Mitchell G. Lawrence, Gail P. Risbridger, Karen L. MacKenzie, Rosemary Sutton, Richard B. Lock

Research output: Contribution to journalArticleResearchpeer-review

5 Citations (Scopus)

Abstract

Patient derived xenografts (PDXs) have become a vital, frequently used, component of anti-cancer drug development. PDXs can be serially passaged in vivo for years, and shared across laboratories. As a consequence, the potential for mis-identification and cross-contamination is possible, yet authentication of PDXs appears limited. We present a PDX Authentication System (PAS), by combining a commercially available OpenArray assay of single nucleotide polymorphisms (SNPs) with in-house R studio programs, to validate PDXs established in individual mice from acute lymphoblastic leukemia biopsies. The PAS is sufficiently robust to identify contamination at levels as low as 3%, similar to the gold standard of short tandem repeat (STR) profiling. We have surveyed a panel of PDXs established from 73 individual leukemia patients, and found that the PAS provided sufficient discriminatory power to identify each xenograft. The identified SNP-discrepant PDXs demonstrated distinct gene expression profiles, indicating a risk of contamination for PDXs at high passage number. The PAS also allows for the authentication of tumor cells with complex karyotypes from solid tumors including prostate cancer and Ewing’s sarcoma. This study highlights the demands of authenticating PDXs for cancer research, and evaluates a reliable authentication platform that utilizes a commercially available and cost-effective system.

Original languageEnglish
Pages (from-to)60475-60490
Number of pages16
JournalOncotarget
Volume7
Issue number37
DOIs
Publication statusPublished - 9 Aug 2016

Keywords

  • Authentication
  • OpenArray
  • Patient derived xenografts
  • R studio
  • SNP genotyping

Cite this

El-Hoss, J., Jing, D., Evans, K., Toscan, C., Xie, J., Lee, H., ... Lock, R. B. (2016). A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. Oncotarget, 7(37), 60475-60490. https://doi.org/10.18632/oncotarget.11125
El-Hoss, Jad ; Jing, Duohui ; Evans, Kathryn ; Toscan, Cara ; Xie, Jinhan ; Lee, Hyunjoo ; Taylor, Renea A. ; Lawrence, Mitchell G. ; Risbridger, Gail P. ; MacKenzie, Karen L. ; Sutton, Rosemary ; Lock, Richard B. / A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. In: Oncotarget. 2016 ; Vol. 7, No. 37. pp. 60475-60490.
@article{388572c95b484c71b4769ac9466f62cf,
title = "A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts",
abstract = "Patient derived xenografts (PDXs) have become a vital, frequently used, component of anti-cancer drug development. PDXs can be serially passaged in vivo for years, and shared across laboratories. As a consequence, the potential for mis-identification and cross-contamination is possible, yet authentication of PDXs appears limited. We present a PDX Authentication System (PAS), by combining a commercially available OpenArray assay of single nucleotide polymorphisms (SNPs) with in-house R studio programs, to validate PDXs established in individual mice from acute lymphoblastic leukemia biopsies. The PAS is sufficiently robust to identify contamination at levels as low as 3{\%}, similar to the gold standard of short tandem repeat (STR) profiling. We have surveyed a panel of PDXs established from 73 individual leukemia patients, and found that the PAS provided sufficient discriminatory power to identify each xenograft. The identified SNP-discrepant PDXs demonstrated distinct gene expression profiles, indicating a risk of contamination for PDXs at high passage number. The PAS also allows for the authentication of tumor cells with complex karyotypes from solid tumors including prostate cancer and Ewing’s sarcoma. This study highlights the demands of authenticating PDXs for cancer research, and evaluates a reliable authentication platform that utilizes a commercially available and cost-effective system.",
keywords = "Authentication, OpenArray, Patient derived xenografts, R studio, SNP genotyping",
author = "Jad El-Hoss and Duohui Jing and Kathryn Evans and Cara Toscan and Jinhan Xie and Hyunjoo Lee and Taylor, {Renea A.} and Lawrence, {Mitchell G.} and Risbridger, {Gail P.} and MacKenzie, {Karen L.} and Rosemary Sutton and Lock, {Richard B.}",
year = "2016",
month = "8",
day = "9",
doi = "10.18632/oncotarget.11125",
language = "English",
volume = "7",
pages = "60475--60490",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "37",

}

El-Hoss, J, Jing, D, Evans, K, Toscan, C, Xie, J, Lee, H, Taylor, RA, Lawrence, MG, Risbridger, GP, MacKenzie, KL, Sutton, R & Lock, RB 2016, 'A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts', Oncotarget, vol. 7, no. 37, pp. 60475-60490. https://doi.org/10.18632/oncotarget.11125

A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts. / El-Hoss, Jad; Jing, Duohui; Evans, Kathryn; Toscan, Cara; Xie, Jinhan; Lee, Hyunjoo; Taylor, Renea A.; Lawrence, Mitchell G.; Risbridger, Gail P.; MacKenzie, Karen L.; Sutton, Rosemary; Lock, Richard B.

In: Oncotarget, Vol. 7, No. 37, 09.08.2016, p. 60475-60490.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts

AU - El-Hoss, Jad

AU - Jing, Duohui

AU - Evans, Kathryn

AU - Toscan, Cara

AU - Xie, Jinhan

AU - Lee, Hyunjoo

AU - Taylor, Renea A.

AU - Lawrence, Mitchell G.

AU - Risbridger, Gail P.

AU - MacKenzie, Karen L.

AU - Sutton, Rosemary

AU - Lock, Richard B.

PY - 2016/8/9

Y1 - 2016/8/9

N2 - Patient derived xenografts (PDXs) have become a vital, frequently used, component of anti-cancer drug development. PDXs can be serially passaged in vivo for years, and shared across laboratories. As a consequence, the potential for mis-identification and cross-contamination is possible, yet authentication of PDXs appears limited. We present a PDX Authentication System (PAS), by combining a commercially available OpenArray assay of single nucleotide polymorphisms (SNPs) with in-house R studio programs, to validate PDXs established in individual mice from acute lymphoblastic leukemia biopsies. The PAS is sufficiently robust to identify contamination at levels as low as 3%, similar to the gold standard of short tandem repeat (STR) profiling. We have surveyed a panel of PDXs established from 73 individual leukemia patients, and found that the PAS provided sufficient discriminatory power to identify each xenograft. The identified SNP-discrepant PDXs demonstrated distinct gene expression profiles, indicating a risk of contamination for PDXs at high passage number. The PAS also allows for the authentication of tumor cells with complex karyotypes from solid tumors including prostate cancer and Ewing’s sarcoma. This study highlights the demands of authenticating PDXs for cancer research, and evaluates a reliable authentication platform that utilizes a commercially available and cost-effective system.

AB - Patient derived xenografts (PDXs) have become a vital, frequently used, component of anti-cancer drug development. PDXs can be serially passaged in vivo for years, and shared across laboratories. As a consequence, the potential for mis-identification and cross-contamination is possible, yet authentication of PDXs appears limited. We present a PDX Authentication System (PAS), by combining a commercially available OpenArray assay of single nucleotide polymorphisms (SNPs) with in-house R studio programs, to validate PDXs established in individual mice from acute lymphoblastic leukemia biopsies. The PAS is sufficiently robust to identify contamination at levels as low as 3%, similar to the gold standard of short tandem repeat (STR) profiling. We have surveyed a panel of PDXs established from 73 individual leukemia patients, and found that the PAS provided sufficient discriminatory power to identify each xenograft. The identified SNP-discrepant PDXs demonstrated distinct gene expression profiles, indicating a risk of contamination for PDXs at high passage number. The PAS also allows for the authentication of tumor cells with complex karyotypes from solid tumors including prostate cancer and Ewing’s sarcoma. This study highlights the demands of authenticating PDXs for cancer research, and evaluates a reliable authentication platform that utilizes a commercially available and cost-effective system.

KW - Authentication

KW - OpenArray

KW - Patient derived xenografts

KW - R studio

KW - SNP genotyping

UR - http://www.scopus.com/inward/record.url?scp=84991327753&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11125

DO - 10.18632/oncotarget.11125

M3 - Article

VL - 7

SP - 60475

EP - 60490

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 37

ER -